Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7952W HIGH $5.18
Volume
52.59 K
Value Traded
389.25 K
Short % Float
10.32%
-1.45%Week
-4.67%1 Month
-16.73%3 Month
-43.18%6 Month
-90.67%5 Year
-99.63%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
42.91 M
EPS (TTM)
-0.96
P/E Ratio
-
Ent. Value
29.16 M
Total Shares
21.04 M
Float Shares
17.11 M
Insiders
18.68%
Institutions
31.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GRCE Catalyst Timeline
Dated clinical, regulatory and corporate events for Grace Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Grace Therapeutics, Inc.
279Total events
7Upcoming
72Tier-1 (high impact)
2013 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Manufacturing MilestoneGTX-104FiledCMC / Inspection
Technology transfer to second U.S.-based contract manufacturer underway
aSAHsource ↗
●Type A MeetingGTX-104FiledFDA Meeting
Type A Meeting held with FDA to discuss CRL
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲FDA Feedback ReceivedGTX-104FiledFDA Meeting
Received Type A meeting minutes from FDA
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
●Runway Guidance UpdateCorporate
Cash runway into Q3 2026, potentially into Q2 2027 if warrants exercised
◆Type A MeetingGTX-104FiledFDA Meeting
Type A meeting scheduled with FDA to discuss NDA resubmission path
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
◆Type A MeetingGTX-104FiledFDA Meeting
Type A meeting scheduled with FDA to clarify path to resubmission
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
◆PDUFA DateGTX-104FiledRegulatory Filing
PDUFA target date for GTx-104 NDA
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
▼Complete Response LetterGTX-104FiledFDA Decision
FDA issued Complete Response Letter for GTx-104 NDA
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲FDA Filing AcceptedGTX-104FiledRegulatory Filing
FDA acceptance for review of NDA for GTx-104
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
◆Poster PresentationGTX-104FiledPresentation
Abstract accepted for poster presentation at AAN 2026
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
●Oral PresentationGTX-104FiledPresentation
Phase 3 STRIVE-ON trial results presented at 2026 American Academy of Neurology
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▼Complete Response LetterGTX-104FiledFDA Decision
FDA issued Complete Response Letter for GTx-104 NDA
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
◆Oral PresentationGTX-104FiledPresentation
Industry education workshop at SCCM Critical Care Congress discussing unmet needs in aSAH and GTx-104 data
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
◆Poster PresentationGTX-104FiledPresentation
Poster on safety and tolerability of GTx-104 vs oral nimodipine at AANN annual meeting
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
●Oral PresentationGTX-104FiledPresentation
Phase 3 STRIVE-ON trial results presented at American Association of Neuroscience Nurses
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
◆Oral PresentationPresentation
Grace Therapeutics to present at TD Cowen 46th Annual Health Care Conference
▼Program DiscontinuationGTX-101DiscontinuedCorporate
Full impairment of IPR&D for GTx-101 and GTx-102
▼Program DiscontinuationGTX-102DiscontinuedCorporate
Full impairment of IPR&D for GTx-101 and GTx-102
◆Oral PresentationGTX-104FiledPresentation
Oral presentation of STRIVE-ON safety trial results at SVIN annual meeting
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
●Oral PresentationGTX-104FiledPresentation
Phase 3 STRIVE-ON trial results presented at Society of Vascular and Interventional Neurology
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
◆Oral PresentationPresentation
CEO participation at Craig-Hallum 16th Annual Alpha Select Conference
◆AbstractGTX-104FiledPresentation
Abstract accepted for late-breaking presentation at SVIN annual meeting
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
▲Oral PresentationGTX-104FiledPresentation
Late-breaking presentation of STRIVE-ON trial data at SVIN annual meeting
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲FDA Filing AcceptedGTX-104FiledRegulatory Filing
FDA acceptance for review of NDA for GTx-104
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
▲FDA Filing AcceptedGTX-104FiledRegulatory Filing
FDA acceptance for review of New Drug Application (NDA) for GTx-104
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲Oral PresentationGTX-104FiledPresentation
Safety and Tolerability of GTx-104 (Nimodipine Injection for I.V. Infusion) Compared with Oral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: a Prospective, Randomized Trial presented at 2025 Neurocritical Care Annual Meeting
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲Patent GrantedGTX-104FiledIP / Competition
U.S. Patent No. 12,414,943 granted covering I.V. dosing regimen for GTx-104
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲FDA Filing AcceptedGTX-104FiledRegulatory Filing
FDA accepted NDA for GTx-104 for formal review
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
●NDA SubmissionGTX-104FiledRegulatory Filing
NDA submission to FDA for GTx-104 in aSAH
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲Primary Endpoint MetGTX-104FiledClinical Data
STRIVE-ON trial met primary endpoint of clinically significant hypotension
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▼Program DiscontinuationGTX-102DiscontinuedCorporate
Deprioritization of GTx-102 development
Ataxia-Telangiectasia (A-T)source ↗
▼Program DiscontinuationGTX-101DiscontinuedCorporate
Deprioritization of GTx-101 development
postherpetic neuralgia (PHN)source ↗
◆Timing GuidanceGTX-104FiledPresentation
FDA acceptance of NDA for review (expected within 60 days)
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
●NDA SubmissionGTX-104FiledRegulatory Filing
NDA submission to FDA for GTx-104
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
▲Primary Endpoint MetGTX-104FiledClinical Data
STRIVE-ON met primary endpoint: 19% reduction in clinically significant hypotension
aneurysmal Subarachnoid Hemorrhage (aSAH)source ↗
●Type C MeetingGTX-104FiledFDA Meeting
Held Type C meeting with FDA on planned NDA submission
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
▲Topline ReadoutGTX-104FiledClinical Data
Positive topline data from Phase 3 STRIVE-ON safety trial
aneurysmal subarachnoid hemorrhage (aSAH)source ↗
Past FDA Catalysts and PDUFA Decisions
How GRCE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-23 | GTx-104 (injectable formulation of nimodipine) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$62M
Pipeline Value
Fair Value
Valuation Signal
1
Drugs Scored
1.4x
rNPV / MCap
Top 44%
Micro Cap(rank 290 of 658)
Percentile Rank
Grace Therapeutics, Inc. faces pipeline headwinds (38/100), with $1.4B risk-adjusted pipeline value, led by GTX-104 in Aneurysmal Subarachnoid Hemorrhage (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GTX-104 Small moleculeNCT05995405 | Aneurysmal Subarachnoid Hemorrhage | Phase 3 | ACTIVE NOT_RECRUITING | 158 | Dec 1, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every GRCE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GTx-104 Orphan | aneurysmal subarachnoid hemorrhage (aSAH) | Phase 3 | 2026-04-14 | reduction in hypotension: 19%; hypotension GTx 104: 28%; hypotension nimodipine: 35%; RDI 95 percent or higher GTx 104: 54%; RDI 95 percent or higher nimodipine: 8%; favorable outcomes increase: 29%Read More | Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% Owner | Buy | 1,694 2,858,657 held | $2.06 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GRCE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GRCE for Q2 2026. | ||||
GRCE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GRCE ranks across every disease it competes in
Competitive Position is a premium feature
See how GRCE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGRCE News
GRCEGrace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
Grace Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Prashant Kohli will present the company's clinical-stage drug GTx-104, which targets aSAH, and will be available for one-on-one meetings with investors. The conference aims to showcase investment opportunities in the biopharma sector.
Read more →GRCEGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics reported its first quarter 2027 financial results, highlighting progress towards resubmitting its New Drug Application (NDA) for GTx-104. The FDA's Complete Response Letter did not identify clinical deficiencies, focusing instead on manufacturing and non-clinical data. The company secured $10 million in financing to support its efforts and is implementing a dual-source manufacturing strategy to mitigate risks.
Read more →GRCEGrace Therapeutics Announces $10 Million Private Placement
Grace Therapeutics has announced a $10 million private placement financing to support the development of GTx-104, a novel injectable formulation for treating aSAH. The financing will close on August 6, 2026, and the proceeds will extend the company's cash runway until the end of 2028. The company is also implementing a dual-source manufacturing strategy to address compliance issues with its current manufacturer.
Read more →GRCEGrace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
Grace Therapeutics has received Type A meeting minutes from the FDA regarding their drug GTx-104, which did not reveal any clinical safety or efficacy issues. The company is addressing manufacturing compliance concerns and plans to resubmit their NDA. They are also implementing a dual-source manufacturing strategy to enhance compliance and reduce risks.
Read more →GRCE▲ +7.2%on this news
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Grace Therapeutics reported its fiscal year-end results for 2026, focusing on GTx-104, an injectable formulation of nimodipine for aSAH. The company is preparing to resubmit its NDA following a Complete Response Letter from the FDA. Positive Phase 3 trial results were shared at major conferences, and the company holds multiple patents for GTx-104. Despite a decrease in net loss, financial challenges remain as cash reserves have diminished.
Read more →GRCE▲ +7.2%on this newsshared move
Corporate Presentation June 2026 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of th
Grace Therapeutics, Inc. presented findings related to its GTx-104 drug candidate, a novel intravenous formulation aimed at treating patients with aneurysmal subarachnoid hemorrhage (aSAH). A pivotal Phase 3 safety trial demonstrated its effectiveness compared to current oral nimodipine treatments. However, the company received an FDA Complete Response Letter citing deficiencies in its chemistry, manufacturing, and controls data. A Type A meeting with the FDA is scheduled to seek clarity on the next steps for the drug's regulatory submission.
Read more →GRCE▼ -6.1%on this news
Corporate Presentation April 2026 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of t
Grace Therapeutics, Inc. presented forward-looking statements regarding their drug candidate GTx-104, aimed at treating acute brain injury due to aneurysmal subarachnoid hemorrhage (aSAH). The FDA issued a Complete Response Letter citing issues with the chemistry, manufacturing, and controls (CMC) data package. Despite these challenges, the company plans to resubmit its New Drug Application (NDA) after meetings with the FDA for clarification on the path forward. The drug is noted for its potential benefits compared to the oral formulation of nimodipine, particularly in addressing significant unmet medical needs.
Read more →GRCEGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
Grace Therapeutics received a Complete Response Letter from the FDA regarding its New Drug Application for GTx-104, intended for treating aneurysmal subarachnoid hemorrhage. The letter cited issues related to Chemistry, Manufacturing, and Controls, but did not request additional clinical data. The company plans to address these issues and resubmit the application after a Type A meeting with the FDA.
Read more →GRCE▼ -45.5%on this newsshared move
GTx-104 FDA Approval
Grace Therapeutics announced that the FDA issued a Complete Response Letter for GTx-104, citing issues in Chemistry, Manufacturing, and Controls. The company plans to address these items and resubmit its application. The trial showed promising results, including a reduction in hypotension incidents compared to oral nimodipine.
Read more →GRCE▲ +12%on this news
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Grace Therapeutics announced that an abstract detailing the results of the STRIVE-ON Phase 3 trial of GTx-104 has been accepted for presentation at the AAN 2026 meeting. The trial showed that GTx-104 significantly reduced episodes of clinically significant hypotension compared to oral nimodipine. Additionally, GTx-104 demonstrated better relative dose intensity and favorable functional outcomes at 90 days.
Read more →GRCEGrace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
Grace Therapeutics is set to present data on GTx-104, an injectable formulation of nimodipine, at two major medical conferences in March 2026. The presentations will focus on the unmet medical needs in treating aneurysmal subarachnoid hemorrhage (aSAH) and the advantages of GTx-104 over oral nimodipine. Data from the Phase 3 STRIVE-ON Trial indicates that GTx-104 may improve patient outcomes and tolerability.
Read more →GRCEGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Grace Therapeutics will participate in the TD Cowen 46th Annual Health Care Conference, with CEO Prashant Kohli presenting on March 4, 2026. The company is advancing GTx-104, an injectable formulation of nimodipine for treating aneurysmal subarachnoid hemorrhage (aSAH). GTx-104 aims to address significant unmet medical needs in this patient population.
Read more →GRCEGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
Grace Therapeutics reported its third quarter 2026 financial results, highlighting progress on its GTx-104 drug candidate for aneurysmal Subarachnoid Hemorrhage (aSAH). The FDA has set a PDUFA target date of April 23, 2026, for the review of GTx-104's NDA submission. The company also presented positive data from the Phase 3 STRIVE-ON trial, which demonstrated improved clinical outcomes for patients treated with GTx-104.
Read more →GRCEGrace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
Grace Therapeutics, Inc. (Nasdaq: GRCE) has announced its participation in the 16th Annual Craig-Hallum Alpha Select Conference, scheduled for November 18, 2025. CEO Prashant Kohli will present at this invitation-only event, which showcases smaller public companies believed to have significant growth potential. The company is developing GTx-104, a novel intravenous formulation of nimodipine targeting unmet medical needs in patients with aneurysmal subarachnoid hemorrhage (aSAH), an uncommon but serious condition. GTx-104 has shown to be well tolerated in clinical studies, potentially offering better management of hypotension in aSAH patients.
Read more →GRCEGrace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
Grace Therapeutics announced the FDA's acceptance of their NDA for GTx-104, aimed at treating aneurysmal Subarachnoid Hemorrhage (aSAH), with a PDUFA target date set for April 23, 2026. The company highlighted positive outcomes from the Phase 3 STRIVE-ON trial, which demonstrated improved clinical results for patients. Additionally, a new patent for the IV dosing regimen of GTx-104 was granted, enhancing their intellectual property portfolio.
Read more →GRCEGrace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
Grace Therapeutics announced that an abstract for its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 has been accepted for presentation at the Society of Vascular and Interventional Neurology annual meeting. The trial focuses on treating aneurysmal subarachnoid hemorrhage (aSAH) with an innovative injectable formulation of nimodipine. The presentation will occur on November 21, 2025, in Orlando, FL.
Read more →GRCEGrace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
Grace Therapeutics has raised approximately $4.0 million through common warrant exercises following the FDA's acceptance of their New Drug Application for GTx-104. This drug aims to treat patients with aneurysmal subarachnoid hemorrhage (aSAH) and is supported by positive results from a Phase 3 trial. The FDA has set a PDUFA target date for review on April 23, 2026.
Read more →GRCEGrace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
Grace Therapeutics presented positive results from its Phase 3 STRIVE-ON Safety Trial for GTx-104 at the Neurocritical Care Society annual meeting. The trial demonstrated that GTx-104, an injectable formulation of nimodipine, is safe and well-tolerated in patients with aneurysmal subarachnoid hemorrhage (aSAH). The findings suggest it may outperform oral nimodipine in managing hypotension and improving patient outcomes.
Read more →GRCEGrace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Grace Therapeutics has been granted a new U.S. patent for the intravenous dosing regimen of GTx-104, extending its protection until 2043. This patent complements the existing five patents on the composition of nimodipine, enhancing the company's market exclusivity. The STRIVE-ON safety trial demonstrated GTx-104's potential benefits over oral nimodipine, particularly in managing hypotension in aSAH patients.
Read more →GRCEGrace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Grace Therapeutics, a late-stage biopharma company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company will showcase its lead clinical asset, GTx-104, aimed at treating aneurysmal Subarachnoid Hemorrhage (aSAH). CEO Prashant Kohli will be available for one-on-one meetings with investors during the event.
Read more →About Grace Therapeutics, Inc.
Headquarters103 CARNEGIE CENTER, PRINCETON, NJ, 08540
BIOPHARMAWATCH ELITE PLUS
Trade the next GRCE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime